Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera: A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels
- 28 June 2004
- journal article
- research article
- Published by Elsevier BV in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1689 (2), 103-113
- https://doi.org/10.1016/j.bbadis.2004.02.005
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Therapeutic synthetic polymers: a game of Russian roulette?Drug Discovery Today, 2002
- Capture of Stealth Nanoparticles by the Body’s DefencesCritical Reviews in Therapeutic Drug Carrier Systems, 2001
- Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarctionAmerican Heart Journal, 1998
- Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteinsThe International Journal of Biochemistry & Cell Biology, 1995
- Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitroKidney International, 1994
- Activation of Complement by Fluosol Attributable to the Pluronic Detergent Micelle StructureJournal of Cardiovascular Pharmacology, 1993
- The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1993
- Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol®The American Journal of Cardiology, 1990
- Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionationTransfusion, 1988
- Pulmonary complications after Fluosol administration to patients with life-threatening blood lossCritical Care Medicine, 1985